AtaiBeckley Inc. 8-K

What Happened

• On June 3, 2026 AtaiBeckley Inc. (ATAI) filed a Form 8‑K under Regulation FD saying the company will participate in multiple investor conferences in June 2026 and that management will discuss program updates, including the initiation of the BPL‑003 Phase 3 pivotal ReConnection program. Presentations and meetings are scheduled at the Jefferies Global Healthcare Conference (June 2–4; presentation June 3 at 12:15 PM ET, live webcast), Oppenheimer CNS and Neuro‑Muscular Summit (June 10; presentation June 10 at 1:35 PM ET), HCW Neuro Perspectives Hybrid Conference (June 15–16; presentation June 15 at 7:00 AM ET, virtual), and UBS Virtual CNS Day (June 15; presentation at 4:30 PM ET). Webcasts are available from the company’s Investors Events page.

Key Details

• Filing date: June 3, 2026 (Form 8‑K, Regulation FD disclosure).
• Clinical update: management will discuss initiation of BPL‑003 Phase 3 pivotal ReConnection program.
• Conferences & times: Jefferies Global Healthcare (June 3, 12:15 PM ET, webcast), Oppenheimer CNS (June 10, 1:35 PM ET), HCW Neuro Perspectives (June 15, 7:00 AM ET, virtual webcast), UBS Virtual CNS Day (June 15, 4:30 PM ET).
• Webcasts and presentation materials: accessible via https://ir.ataibeckley.com/investor-relations under Events.

Why It Matters

• Investors should note management will publicly discuss a major clinical milestone — the start of a Phase 3 pivotal program for BPL‑003 — which is a key development event for the company’s pipeline and potential value drivers.
• Scheduled presentations and webcasts give investors direct access to management’s messaging and any program timing or development updates; check the investor‑relations Events page for the live streams.